Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Hartkopf

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Archives of Gynecology and Obstetrics|March 13, 2024
Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registryM L Frevert, D Dannehl, L Jansen, et al.
Archives of Gynecology and Obstetrics|August 18, 2025
Treatment and survival of early non-metastatic breast cancer in men: real world data from a population-based registryD Jakob, D Dannehl, H Endres, et al.
Breast Cancer Research and Treatment|March 16, 2013
The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapseA D Hartkopf, M Banys, F Meier-Stiegen, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|September 12, 2018
High intensity focused ultrasound (HIFU) for the treatment of symptomatic breast fibroadenomaM Hahn, R Fugunt, B Schoenfisch, et al.
Gynecologic Oncology|January 13, 2019
Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine diseaseP Wagner, F K F Kommoss, S Kommoss, et al.
ESMO Open|March 22, 2025
Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assayW Janni, B Rack, T W P Friedl, et al.
ESMO Open|April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)P Meyer-Wilmes, J Huober, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trialsM Graeser, O Gluz, C Zu Eulenburg, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Archives of Gynecology and Obstetrics|March 13, 2024
Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registryM L Frevert, D Dannehl, L Jansen, et al.
Archives of Gynecology and Obstetrics|August 18, 2025
Treatment and survival of early non-metastatic breast cancer in men: real world data from a population-based registryD Jakob, D Dannehl, H Endres, et al.
Breast Cancer Research and Treatment|March 16, 2013
The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapseA D Hartkopf, M Banys, F Meier-Stiegen, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|September 12, 2018
High intensity focused ultrasound (HIFU) for the treatment of symptomatic breast fibroadenomaM Hahn, R Fugunt, B Schoenfisch, et al.
Gynecologic Oncology|January 13, 2019
Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine diseaseP Wagner, F K F Kommoss, S Kommoss, et al.
ESMO Open|March 22, 2025
Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assayW Janni, B Rack, T W P Friedl, et al.
ESMO Open|April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)P Meyer-Wilmes, J Huober, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trialsM Graeser, O Gluz, C Zu Eulenburg, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Pageof 2